Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 49.7% in February

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 28,034 shares, a decrease of 49.7% from the January 29th total of 55,704 shares. Based on an average daily trading volume, of 72,588 shares, the short-interest ratio is currently 0.4 days. Approximately 0.6% of the company’s stock are short sold. Approximately 0.6% of the company’s stock are short sold. Based on an average daily trading volume, of 72,588 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is currently owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Stock Down 5.9%

NASDAQ GLMD traded down $0.04 during midday trading on Friday, hitting $0.61. The company had a trading volume of 16,760 shares, compared to its average volume of 72,599. The firm has a fifty day simple moving average of $0.74 and a two-hundred day simple moving average of $1.09. Galmed Pharmaceuticals has a fifty-two week low of $0.50 and a fifty-two week high of $3.50. The stock has a market cap of $3.35 million, a price-to-earnings ratio of -1.91 and a beta of 0.40.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Galmed Pharmaceuticals presently has an average rating of “Reduce”.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.